CD58

Across TCGA pan-cancer cohorts, CD58 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated CD58 data layer compared with 27 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher CD58 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated CD58 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

UCEC, LUAD, and LSCC are the cancer types where CD58 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCEC	OS	Quartile	All	1.000	0.764	.006	24	view →
LUAD	OS	Median	II,III,IV	0.474	0.809	.004	20	view →
LSCC	DFS	Quartile	All	0.422	0.986	.031	3	view →
CCRCC	DFS	Tertile	III,IV	0.198	0.887	.024	3	view →
GBM	OS	Tertile	All	0.722	0.912	.039	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

CD58–UCEC (OS)

Open the UCEC breakdown →